Asenta

Quick links to important sections

Asenta

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asenta

Quick Facts

Property Description
Active ingredient Donepezil hydrochloride
Form Oral tablets (film-coated, ODT)
Pharmacological class Acetylcholinesterase inhibitor (AChEI)
General purpose Symptomatic maintenance therapy for cognitive support
Origin Synthetic piperidine derivative

What Type of Medicine is Asenta (Donepezil)?

Asenta is a prescription-only medication with the active ingredient Donepezil hydrochloride, which is a synthetic, centrally acting agent. It belongs to the pharmacological class of acetylcholinesterase inhibitors (AChEIs), a group of compounds developed to affect neurotransmitter levels in the brain. This reflects the drug's role in influencing brain chemistry for therapeutic effect. As a piperidine derivative, Donepezil is a synthetically produced compound designed for its selective and reversible action within the central nervous system.

The Pharmaceutical Form of Asenta

The medication is supplied as a single-ingredient product designed for oral administration. The primary forms available are stable, solid oral preparations, specifically film-coated tablets. A distinguishing feature of its formulation is the availability of orally disintegrating tablets (ODT), offering patients a different route of ingestion that does not require water. The composition centers on the Donepezil hydrochloride active substance integrated with the necessary pharmaceutical excipients to create these consistent tablet delivery systems.

General Therapeutic Purpose of Asenta

The essential function of Asenta lies in its designation as a cognition-enhancing drug used for symptomatic maintenance therapy in adult patients. Its purpose is rooted in its mechanism as an acetylcholinesterase inhibitor, which supports nerve cell communication by helping to preserve a key neurotransmitter in the brain called acetylcholine. For example, in typical use scenarios, the medication is intended to offer support for the maintenance of cognitive abilities, including memory and thinking functions, during periods of decline.

Regulatory References

  1. Donepezil: MedlinePlus Drug Information

What side effects are possible with Asenta?

Asenta (sertraline) is a prescription medication, and like all drugs, it can cause side effects. Patients should be closely monitored by a healthcare provider while taking this medication.

Important Safety Information

Suicidal Thoughts and Behavior: Antidepressants, including Asenta, may increase the risk of suicidal thoughts and actions in children, adolescents, and young adults (up to age 24), particularly when starting treatment or when the dosage is changed. This risk must be balanced with the clinical need, and all patients should be closely observed for any unusual changes in behavior, agitation, or worsening depression.

Serotonin Syndrome: This potentially life-threatening condition can occur when Asenta is taken alone, but the risk is higher when combined with other medications that increase serotonin (e.g., triptans, other antidepressants, tramadol). Symptoms may include agitation, hallucinations, confusion, sweating, fever, fast heart rate, muscle stiffness, or twitching.

  • Other Serious Concerns: Other serious side effects may include activation of mania or hypomania in patients with undiagnosed bipolar disorder, angle-closure glaucoma, low sodium levels in the blood (hyponatremia), and an increased risk of bleeding or bruising, especially when taken with blood thinners or NSAIDs.

Common Side Effects

The following are among the most frequently reported side effects, which often decrease after the first few weeks as the body adjusts to the medication:

System Common Side Effects (Affecting ge 5% of patients)
Gastrointestinal Nausea, diarrhea/loose stools, dry mouth, indigestion, decreased appetite
Nervous System Insomnia, somnolence (drowsiness), dizziness, tremor, fatigue
Sexual Decreased libido, ejaculation failure, difficulty achieving orgasm
General Increased sweating (hyperhidrosis)

Do not stop taking Asenta suddenly without consulting your doctor, as this can lead to withdrawal symptoms.

Overdose and Emergency Response

Overdose with Donepezil hydrochloride may result in a severe state officially documented as a cholinergic crisis, an intensification of the drug's intended action. Immediate medical attention is required for any suspected overdose or when signs of this crisis are present.

Documented Overdose Manifestations

Symptoms documented in official prescribing information include severe nausea and vomiting, excessive salivation and sweating, and specific neuromuscular issues such as increasing muscle weakness and fasciculations (muscle twitching). Cardiovascular signs include bradycardia (slow heart rate) and hypotension (low blood pressure).

Severe Outcomes and Emergency Action

Overdosage carries the risk of life-threatening outcomes, particularly respiratory depression, convulsions, and collapse. Due to the potential for severe cardiac conduction abnormalities, regulators mandate that individuals exhibiting these signs must seek immediate medical attention and be transported to a hospital for observation.

Supportive Management

In a hospital setting, management involves general supportive measures. The official antidote described for treating the peripheral cholinergic effects is atropine sulfate. Specific procedures may include gastric lavage and the administration of activated charcoal. Close ECG monitoring is required as part of the mandatory hospital observation until clinical stability is achieved.

Therapeutic Uses of Asenta

What Asenta Treats: Main Uses and Benefits

Asenta (donepezil) is generally used as a symptomatic maintenance therapy for the management of conditions involving episodic or fluctuating manifestations, notably dementia of the Alzheimer's type. The medication is used in situations involving certain distressing symptoms across the spectrum of the disease. It may be part of symptomatic management applied in clinical settings marked by cognitive decline.

The medication is applied in addressing symptom clusters related to cognitive impairment. This commonly includes issues with memory loss, reduced attention, and general challenges in thinking clearly. The therapeutic approach plays a role in managing the overall symptom burden. It provides supportive relief when symptoms interfere with routine activities, and assists with maintaining functional stability.

“It is commonly used to help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.”


Quick Fact: Support for Cognitive Symptoms
Therapeutic Role Symptomatic management for memory and thinking impairments.
Symptom Focus Memory loss, attention deficits, and general thinking clarity.
Patient Benefit Assists with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Asenta — Official Regulatory Information

The eligibility for Asenta (Donepezil) is defined by regulatory documents based on age, pre-existing conditions, and hypersensitivity. This outlines who may use the medicine and who is restricted or formally prohibited.

Eligibility Scope
Populations for whom use is allowed: Adults (aged 18 and older) are the only population in which safety and efficacy have been established for approved use.
Populations for whom use is contraindicated: Patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives are absolutely prohibited from use.
Populations for whom use is not recommended: Pediatric patients (under 18 years) because safety and efficacy have not been established. Use is also not recommended during pregnancy or lactation.
Condition-specific eligibility rules: Caution is required for use in patients with pre-existing conditions, including cardiac conduction abnormalities (risk of bradycardia), active peptic ulcer disease, asthma, or obstructive pulmonary disease.
Organ function restrictions: While no dose adjustment is typically needed for renal impairment, use has not been established in patients with severe hepatic (liver) impairment.

Connection to the overall eligibility profile: Regulatory documents define eligibility by establishing absolute contraindications based on compound allergy and by imposing conditional use restrictions based on specific comorbid conditions or physiological states. This framework restricts use to adults while advising caution or non-use for vulnerable populations where safety is not established.

What should I know about interactions with other medicines?

Official Interaction Profile for Asenta (Donepezil)

The interaction profile for Asenta is formally documented in government regulatory sources, establishing patterns based on metabolic pathways and pharmacodynamic effects.

Pharmacokinetic Interactions (Exposure Modification)

Donepezil is metabolized by the cytochrome P450 isoenzymes CYP3A4 and CYP2D6. Co-administration with strong inhibitors of these enzymes, such as Ketoconazole (a CYP3A4 inhibitor) or Fluoxetine (a CYP2D6 inhibitor), is officially documented to increase the plasma concentration of Donepezil. Conversely, enzyme inducers, including Rifampicin and Carbamazepine, may reduce exposure to Donepezil by increasing metabolic clearance.

Pharmacodynamic Interactions (Additive Effects)

Due to its established cholinergic activity, a synergistic effect may occur with co-administered cholinergic agonists. The medication has the potential to interfere with the activity of anticholinergic drugs and is likely to exaggerate the effects of depolarizing neuromuscular blocking agents, such as succinylcholine, during anesthesia. Co-administration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) carries an officially documented increased risk of gastrointestinal bleeding and peptic ulcers.

Contraindications and Population Notes

Donepezil is contraindicated in patients with known hypersensitivity to the drug or to other piperidine derivatives. Regulatory information notes that clearance is decreased by approximately 20% in individuals with stable alcoholic cirrhosis, altering exposure in that population. The absorption of the film-coated tablets is not influenced by food.

Mechanism of Action

Asenta is a central nervous system (CNS) agent, identified as donepezil hydrochloride (Source 1.8). It readily crosses the blood-brain barrier (Source 1.1). Its primary biological target is the enzyme acetylcholinesterase (AChE) (Source 1.1, 1.4). Asenta functions as a rapid and reversible inhibitor of AChE (Source 1.1). This interaction prevents the hydrolysis (breakdown) of the neurotransmitter acetylcholine (ACh) in the synaptic cleft (Source 1.1). This enzymatic inhibition results in a net increase in the concentration and duration of action of acetylcholine at cholinergic synapses (Source 1.1, 1.4). This enhanced cholinergic transmission represents the main molecular pathway of its action (Source 1.1). Downstream consequences include the modulation of neuroinflammatory responses via downregulation of microglial and astrocytic activation (Source 1.1). Furthermore, non-cholinergic mechanisms include the upregulation of nicotinic receptors in cortical neurons (Source 1.1). At a system level, this modulation of cholinergic neurotransmission and other downstream signaling pathways contributes to overall central nervous system function (Source 1.1).

Dosage and Administration Information

How Asenta is Used: General Administration Guidelines

Asenta (donepezil) is administered according to a structured protocol. The medicine is primarily available in oral forms, including film-coated tablets, orally disintegrating tablets (ODT), and oral solution, but is also available as a transdermal system (patch).


Standard Dosing and Schedule

Donepezil therapy is initiated at a low dose and follows a gradual titration schedule to allow the body to adjust to the medication. The common initial dose is 5 mg taken once daily. This starting dose is typically maintained for a sustained period, typically four to six weeks, before any dose increase is considered.

Category General Instruction
Timing Oral forms are generally taken in the evening, just prior to retiring.
Food Relationship The medicine can be taken with or without food.
Maximum Dose The maximum dose is 10 mg once daily in many regions, while some protocols include a 23 mg dose for specific patient populations.

Administration and Handling

To ensure proper use, specific handling rules apply to certain formulations. Orally disintegrating tablets (ODT) should be placed on the tongue, allowed to dissolve, and then swallowed. The 23 mg tablet, where prescribed, must not be split, crushed, or chewed to avoid altering the controlled rate of absorption.

Population and Missed Doses

There are generally no dose adjustments specified for patients with renal impairment. However, use in patients with mild to moderate hepatic impairment requires caution during dose escalation. If a single dose is missed, it is generally advised to skip that dose and take the next one at the normal scheduled time.

Recent Clinical Evidence

Asenta: Recent Clinical Evidence

Research has explored the profile of Asenta (sacituzumab govitecan-hziy) in the management of specific advanced cancers, primarily focusing on triple-negative breast cancer (TNBC) and hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer.

Phase 3 Trial Findings (ASCENT)

Studies evaluated Asenta's profile compared to single-agent chemotherapy (Treatment of Physician's Choice, TPC) in patients with metastatic TNBC who had previously received multiple therapies. This international, randomized, open-label Phase 3 trial (ASCENT) served as a key basis for regulatory evaluation.

Research examined several key endpoints in this population, with final analysis results suggesting a difference in outcomes for participants receiving Asenta versus TPC. The median progression-free survival (PFS) was evaluated, and studies also reported on overall survival (OS) in this cohort. Researchers tracked the overall safety profile, including the incidence and severity of reported side effects, across both treatment arms.

Endpoint Evaluated Comparator (TPC) Asenta Type of Analysis
Progression-Free Survival (PFS) 1.7 months 4.8 months Median Value Reported
Overall Survival (OS) 6.9 months 11.8 months Median Value Reported

Ongoing and Future Research

Clinical development continues to investigate the potential of Asenta in earlier lines of treatment and in combination with other anti-cancer agents, such as pembrolizumab. Ongoing trials, including ASCENT-07, are evaluating its profile in patients with HR+/HER2- metastatic breast cancer who have progressed following endocrine therapy. These studies seek to further assess its impact on overall survival and disease progression rates in different cancer types and stages.

Frequently Asked Questions (FAQ)

Common questions about Asenta (FAQ)


Q: Is Asenta only used for the condition described in the advertising materials?

Official regulatory documents state the specific uses, or indications, for which Asenta has been approved based on established safety and effectiveness. The medicine is described for these specific conditions. Any use outside of these approved conditions is not addressed in the official product information.


Q: What are the official benefits of taking Asenta as stated in regulatory documents?

According to official product information, Asenta is intended for symptomatic maintenance therapy to support cognitive abilities like memory and thinking. Studies have shown that for some patients, metrics such as progression-free or overall survival differences were reported when compared to other treatments.


Q: Does taking Asenta require any special monitoring by a healthcare provider?

Official documents recommend close observation by a healthcare provider while taking this medicine. This monitoring is typically advised during the initial phase of treatment or when the dosage is adjusted. The focus is on watching for any unusual changes in behavior or potential side effects.


Q: What is the expected timeline for a patient if Asenta doesn't seem to be working?

Regulatory protocols typically establish a period, such as four to six weeks, at the starting dose before a dose adjustment is officially considered. This defined timeframe serves as the first official timeline for assessing a patient's response to the medicine. Any change in the treatment plan is a clinical decision made by the prescribing doctor.


Q: Are there any known long-term side effects that have been studied for Asenta?

Regulatory information lists known serious risks associated with chronic use that require ongoing monitoring. These can include an increased risk of suicidal thoughts and behaviors, and the potential for the activation of mania or hypomania in certain individuals.


Q: Can older adults safely be prescribed Asenta?

Official regulatory data confirms that the medicine is authorized for use in adults. However, it notes that specific caution may be necessary when prescribing to older adults, as this population can sometimes have higher sensitivity to medicines or existing conditions that require careful consideration.


Q: How long after stopping Asenta is the medicine expected to be out of the body's system?

The official prescribing information includes the drug's elimination half-life, which is a pharmacokinetic measure used to estimate the time it takes for the medicine to fully clear the body. This is a general estimate based on how the body processes the drug.


Q: Is Asenta a type of pain reliever?

No, regulatory documents describe the medicine's pharmacological class as a Central Nervous System (CNS) agent, specifically an acetylcholinesterase inhibitor. Its primary purpose is symptomatic maintenance therapy to support cognitive function, not primary pain relief.


Q: Is there a risk of developing physical dependence on Asenta if taken for a long time?

Official labeling includes information on the potential for abuse or physical dependence, which is a key regulatory concern. The safety information also explicitly warns against sudden cessation of the drug, as this can lead to uncomfortable discontinuation symptoms.


Q: How soon can a person typically expect to notice any effects from taking Asenta?

Studies and official information indicate that measurable differences in patient outcomes were observed over a certain time frame when compared to a placebo or comparator treatment. The exact time it takes to notice effects varies by individual and the condition being managed.


Q: What is the recommended typical duration of treatment with Asenta?

Official guidance classifies the medicine as being intended for chronic, or maintenance therapy. This means it is generally used on an ongoing basis for long-term management of the condition, and it is not typically described as a short-term treatment.


Q: Are the side effects experienced with Asenta considered permanent?

Regulatory information notes that common side effects often decrease or resolve as the body adjusts to the medication over the first few weeks of treatment. Official documents do not typically label specific side effects as strictly permanent or temporary.


Q: What are the guidelines for reporting a severe side effect from Asenta to a healthcare provider?

Official public information details the appropriate action to take when a severe adverse event occurs. The guidelines describe the need for prompt action, such as contacting a healthcare professional or seeking urgent medical services in an emergency.


Q: Does Asenta commonly cause weight gain or weight loss?

Regulatory documents list specific changes in body weight or appetite changes, which provides the factual basis for addressing questions about weight fluctuations. Official product information indicates whether weight change is listed as a common or uncommon effect among the reported side effects.


Q: Is hair loss listed as a possible side effect of Asenta?

Official documents list reported side effects, which include less common dermatological events. Hair loss, or alopecia, is included in this comprehensive list of possible side effects from the clinical trials.


Q: Can alcohol be consumed while a person is taking Asenta?

Regulatory documents specify if there is a known interaction between the drug and alcohol. Alcohol use may need to be limited or avoided due to the potential risk of additive central nervous system effects.


Q: Are there any specific foods or non-alcoholic drinks to avoid while using Asenta?

Official labeling provides pharmacokinetic data on whether the drug's absorption is significantly influenced by food. This data is the basis for general food interaction advice, which usually suggests whether the medicine should be taken with or without food.


Q: Can Asenta be taken at the same time as common vitamin supplements?

Official labeling focuses primarily on formal drug-drug interactions with prescription medicines. General guidance regarding common vitamin supplements is usually based on the lack of known formal contraindications or specific studies in the official documentation.


Q: Are there known interactions between Asenta and birth control medications?

Potential interactions with birth control medications are assessed based on how the drug is metabolized in the body. If Asenta's metabolic pathways could affect the clearance of birth control steroids, this potential interaction is stated in the official labeling.


Q: Where can members of the public find the official prescribing information for Asenta?

Official government agencies provide public access to the full prescribing information for Asenta. This includes the patient information leaflet, package insert, or the Summary of Product Characteristics (SmPC) via their official websites.


Q: How long has Asenta been commercially available on the market?

Regulatory agencies record the initial date when the medicine received marketing authorization. This official date confirms the length of time Asenta has been commercially available on the market since its initial approval.

How should Asenta be stored and disposed of?

The storage and disposal of Asenta (donepezil hydrochloride) must strictly adhere to regulatory labeling to maintain product stability and ensure safety.

Storage Requirements

The tablets must be stored at controlled room temperature, generally between 20°C to 25°C (68°F to 77°F). It is required that the medicine is kept in the original container and protected from moisture.

Child Safety and Handling

Asenta must be stored out of the sight and reach of children.

Disposal Instructions

Any unused medicinal product or waste material must be disposed of in accordance with local requirements. Government guidance recommends utilizing official drug take-back programs as the preferred method for discarding unused medication. If a take-back program is unavailable, non-flushable medicines should be mixed with an undesirable substance and placed in a sealed container before disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Asenta found in:

A-Z Index: